Economic evaluation of opioid substitution treatment in Greece

dc.contributor.author	Γείτονα, Μαίρη	el
dc.contributor.author	Καραγιάννη, Βιλελμίνη Ι.	el
dc.contributor.author	Πετράτος, Πυθαγόρας	el
dc.date.accessioned	2015-04-15T16:53:03Z
dc.date.available	2015-04-15T16:53:03Z
dc.date.issued	2015-04-15
dc.identifier.uri	http://hdl.handle.net/11400/8408
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.atforum.com	en
dc.subject	Αποτοξίνωση
dc.subject	Rehab
dc.title	Economic evaluation of opioid substitution treatment in Greece	en
heal.type	journalArticle
heal.classification	Medical economics
heal.classification	Drug therapy
heal.classification	Οικονομικά της υγείας
heal.classification	Φαρμακολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85082915
heal.classificationURI	http://skos.um.es/unesco6/611305
heal.classificationURI	N/A-Οικονομικά της υγείας
heal.classificationURI	N/A-Φαρμακολογία
heal.language	en
heal.access	free
heal.recordProvider	Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Δημόσιας Υγείας και Κοινοτικής Υγείας. Κατεύθυνση Δημόσιας Υγείας (Δημόσιας Υγιεινής)	el
heal.publicationDate	2012-09
heal.bibliographicCitation	Geitona, M., Carayanni, V., Petratos, P. (2012) Economic evaluation of opioid substitution treatment in Greece. "Heroin Addiction and Related Clinical Problems", 14 (3), p. 77-88.	en
heal.abstract	We performed an economic evaluation of opioid substitution treatment (OST) in Greece using data from the Greek Organ - ization Against Drugs (OKANA). Cost minimization analysis predicted that buprenorphine monotherapy is more costly than buprenorphine-naloxone therapy. Analyses of cost effectiveness demonstrated that buprenorphine-naloxone was the dominant therapy in terms of mortality avoidance and completion of treatment. Furthermore, compared with methadone, buprenorphine-naloxone reduced the mean cost by 49%; it raised the percentage of participants who completed their treatment ~1.5-fold and reduced the percentage of deaths ~2.5-fold. Budget impact analysis demonstrated that switching to buprenorphine-naloxone treatment would result in significant savings, cut the length of waiting lists, and allow greater access to OST in Greece.	en
heal.journalName	Heroin Addiction and Related Clinical Problems	el
heal.journalType	peer-reviewed
heal.fullTextAvailability	true